Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03208985 · ClinicalTrials.gov registry record · Phase 3
A Study of Use of Ella®, an Emergency Contraceptive, Under Simulated OTC Conditions
A Phase 3 study, sponsored by HRA Pharma.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,270
- Enrollment target
NCT03208985: Completed Phase 3 study, sponsored by HRA Pharma.
NCT03208985 is a Phase 3 study that has completed, run by HRA Pharma. The registered enrollment target is 1,270 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (65% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03208985, a Phase 3 study, has completed, sponsored by HRA Pharma.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,270 participants
- Enrollment target
Study Summary
This study is designed to assess whether consumers select and use ella® (ulipristal acetate 30mg), an emergency contraceptive, in a manner consistent with the OTC package directions in an OTC-like setting.
Primary Outcome
The first primary endpoint is the proportion in which the denominator includes all dosing instances of the IP and the numerator includes all dosing instances of the IP which were taken within 120 hours (5 days) of the subject's most recent episode of unprotected sex.
Interventions
- DRUG Use Phase (Ulipristal Acetate, 30 mg)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,270 participants |
| Start Date | 2017-05-23 |
| Est. Completion | 2018-06-14 |
| Phase | Phase 3 |
What the finished NCT03208985 record still lists
NCT03208985 is an interventional study that assigns participants to a tested intervention. Its 1,270 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (65% higher).
The record links to 0 conditions, and to 1 intervention - of which Use Phase (Ulipristal Acetate, 30 mg) is the first listed.
NCT03208985 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03208985 about?
NCT03208985 is a clinical study titled "A Study of Use of Ella®, an Emergency Contraceptive, Under Simulated OTC Conditions". This study is designed to assess whether consumers select and use ella® (ulipristal acetate 30mg), an emergency contraceptive, in a manner consistent with the OTC package directions in an OTC-like setting.
What is the current status of trial NCT03208985?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,270 participants. The study started on 2017-05-23. Estimated completion is 2018-06-14.
What interventions are being tested in trial NCT03208985?
The interventions under investigation include: Use Phase (Ulipristal Acetate, 30 mg) (DRUG).
Who is sponsoring clinical trial NCT03208985?
This trial is sponsored by HRA Pharma, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03208985's enrollment target sits among peer trials
1,270 202nd of 2000 higher than 1,799 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06790641 · 1,270 participants · NA
Pathways to Perinatal Mental Health Equity
- NCT06876246 · 1,270 participants · NA
SBIR/ STTR Family Check-up Online
- NCT03678025 · 1,273 participants · Phase 3
Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer
- NCT07225504 · 1,275 participants · Phase 3
A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI